Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Schizophrenic disorders: current etiologic and clinical knowledge].

Jean-Pierre Olié1, Marie-Odile Krebs, Henri Lôo

  • 1SHU/ E0117 INSERM, Hôpital Ste Anne- Université Paris V, 1 rue Cabanis, 75674 Paris 14.

Bulletin De L'Academie Nationale De Medecine
|January 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards an integrative and personalized care across the stages of schizophrenia spectrum disorders.

World psychiatry : official journal of the World Psychiatric Association (WPA)·2026
Same author

Hyperdynamic microtubule-based structural changes in Monocyte-Derived-Neuronal-like cells from patients with schizophrenia.

Schizophrenia (Heidelberg, Germany)·2026
Same author

EEG power spectral and microstate analyses in the 22q11.2 deletion syndrome: from genetic risk to schizophrenia.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Neurophysiological Resting-State Markers of Catatonia in Schizophrenia and Mood Disorders.

Schizophrenia bulletin·2026
Same author

Use of service and treatment adequacy in health students with depression.

L'Encephale·2026
Same author

Pharmacogenomics of antiepileptic drug mood stabilizer treatment response in bipolar disorder: A MoStGen Consortium study.

Molecular psychiatry·2026
Same journal

[Advances and perspectives in vascularized composite allotransplantation preservation].

Bulletin de l'Academie nationale de medecine·2025
Same journal

[COVID-19: Neurological manifestations and complications during the acute phase of the disease].

Bulletin de l'Academie nationale de medecine·2024
Same journal

[Role of psychological factors in post-COVID-19 condition].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[From the origin of Sars-CoV-2 to dangerous virology/biology].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[Neurological forms of long COVID in adults: Critical approach].

Bulletin de l'Academie nationale de medecine·2023
Same journal

[Post-COVID-19 syndrome].

Bulletin de l'Academie nationale de medecine·2023
See all related articles

Schizophrenia is a brain disease with early anomalies like atrophy and abnormal gyration, detectable even in healthy relatives. Identifying genetic markers aids in early intervention for better patient outcomes.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Genetics

Context:

  • Schizophrenic disorders exhibit diverse anomalies, including cognitive, neurophysiological, and neurological aspects.
  • Brain imaging reveals early signs like cortical-subcortical atrophy and abnormal gyration, present even in unaffected relatives.

Purpose:

  • To explore the neurobiological underpinnings of schizophrenia and the transition from vulnerability to clinical onset.
  • To investigate genetic factors and biomarkers for early identification of high-risk individuals.

Summary:

  • Schizophrenia is increasingly recognized as a brain disease, supported by neuropathological, neuroimaging, and clinical findings.
  • Cognitive deficits (attention, memory, verbal fluency) and neurophysiological abnormalities (N300, P50 wave modifications) are characteristic.

Related Experiment Videos

  • Neuronal factors, including synaptic transmission and plasticity deficits (e.g., BDNF protein), are implicated, with genetic studies focusing on phenotypic characteristics like P50 modulation and specific genes (COMT, BDNF).

    • Impact:

    • Early identification of high-risk subjects can potentially shorten treatment delays and improve long-term outcomes.
    • Understanding the genetic and neurobiological basis may pave the way for targeted interventions and primary prophylaxis strategies.